Concepts (80)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dasatinib | 6 | 2018 | 881 | 0.460 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 4 | 2018 | 531 | 0.390 |
Why?
|
| Imatinib Mesylate | 6 | 2018 | 1691 | 0.300 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 74 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2018 | 4961 | 0.190 |
Why?
|
| Sentinel Lymph Node | 1 | 2023 | 235 | 0.180 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2016 | 2635 | 0.170 |
Why?
|
| Thiazoles | 2 | 2014 | 723 | 0.170 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2018 | 1161 | 0.160 |
Why?
|
| Chymases | 1 | 2018 | 8 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.150 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 870 | 0.140 |
Why?
|
| Lymphocytosis | 1 | 2016 | 57 | 0.130 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2016 | 114 | 0.130 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 14617 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 5593 | 0.100 |
Why?
|
| Benzamides | 2 | 2014 | 1879 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2014 | 3669 | 0.090 |
Why?
|
| Disease-Free Survival | 6 | 2018 | 10265 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 999 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2022 | 3156 | 0.080 |
Why?
|
| Piperazines | 2 | 2014 | 2145 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 4895 | 0.070 |
Why?
|
| Melanoma | 1 | 2023 | 5595 | 0.060 |
Why?
|
| Papillomaviridae | 2 | 2018 | 636 | 0.060 |
Why?
|
| Pleural Effusion | 2 | 2016 | 228 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2016 | 500 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 7265 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2023 | 233 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2023 | 125 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6256 | 0.050 |
Why?
|
| Optical Imaging | 1 | 2023 | 158 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2018 | 33737 | 0.040 |
Why?
|
| Young Adult | 4 | 2023 | 22251 | 0.040 |
Why?
|
| Treponema denticola | 1 | 2018 | 2 | 0.040 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Middle Aged | 7 | 2023 | 90352 | 0.040 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2018 | 30 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 30998 | 0.040 |
Why?
|
| Male | 8 | 2023 | 128315 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 522 | 0.040 |
Why?
|
| Aged | 6 | 2023 | 73333 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2023 | 9470 | 0.040 |
Why?
|
| Finland | 1 | 2017 | 66 | 0.040 |
Why?
|
| Adult | 6 | 2023 | 82040 | 0.040 |
Why?
|
| Female | 8 | 2023 | 148940 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 218 | 0.030 |
Why?
|
| Azacitidine | 1 | 2022 | 1218 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2017 | 294 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2016 | 119 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2023 | 1458 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 15218 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2023 | 39890 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 984 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 9039 | 0.030 |
Why?
|
| Humans | 10 | 2023 | 270740 | 0.030 |
Why?
|
| Time | 1 | 2014 | 183 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 690 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2013 | 574 | 0.020 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 861 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 2271 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 5408 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 1020 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 613 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 965 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 4048 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 1144 | 0.020 |
Why?
|
| Adolescent | 2 | 2023 | 32767 | 0.020 |
Why?
|
| Prognosis | 2 | 2018 | 22505 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 2027 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 2650 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7655 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 5824 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 9292 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6764 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 9042 | 0.010 |
Why?
|
| Child | 1 | 2023 | 30559 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 14012 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 16689 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 13006 | 0.010 |
Why?
|